Applying Hypertension Clinical Trials to Real World Adults with CKD
将高血压临床试验应用于现实世界中患有 CKD 的成人
基本信息
- 批准号:10494235
- 负责人:
- 金额:$ 64.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAffectAfrican AmericanAttenuatedBenefits and RisksBlood PressureCaliforniaCardiovascular systemCessation of lifeChronic Kidney FailureClinicalClinical TrialsConsensusDataDatabasesDecision MakingDiabetes MellitusDisease ManagementDisease ProgressionElderlyElectronic Health RecordEventGoalsGuidelinesHealthcare SystemsHypertensionIndividualIntervention TrialKidneyKidney DiseasesLaboratoriesLeadModelingParticipantPatientsPersonsPharmaceutical PreparationsPharmacy facilityPopulationRecommendationRenal functionResearch PriorityRiskSecondary PreventionSerious Adverse EventStrokeSubgroupTarget PopulationsUncertaintyVeterans Health Administrationblood pressure interventionblood pressure medicationcardiovascular risk factorclinical decision supportcohortcomparativehigh risk populationhypertension controlhypertension treatmentinnovationmortalitymortality risknovelpatient populationpersonalized predictionsprofiles in patientsrandomized trialsymposiumtreatment effect
项目摘要
PROJECT SUMMARY / ABSTRACT
Hypertension affects more than 80% of adults with chronic kidney disease (CKD), and its treatment is a
cornerstone of CKD management. Clinical guidelines vary in their recommendations for blood pressure targets
in CKD, reflecting uncertainties in the interpretation of the Systolic Blood Pressure Intervention Trial (SPRINT)
and its extrapolation to adults with CKD, particularly those with advanced CKD. Although evidence from
randomized trials has strong internal validity, it may not reflect the risk benefit profile of patient populations that
will receive treatment in practice. Our overarching goal is to evaluate the comparative risks and benefits of
intensive versus standard blood pressure targets in real world adults with CKD. Our secondary goal is to
demonstrate the feasibility and utility of novel analytical approaches that extend causal effects from
randomized trial effects to broader populations. We will accomplish these goals by leveraging electronic health
record data from two large health care systems encompassing 13 million enrollees - the Veterans Health
Administration and Kaiser Permanente of Southern California. To inform our real-world estimates, we will
integrate individual-level data from four diverse hypertension trials on 20,000 participants. In Aim 1, we will
estimate average treatment effects of intensive versus standard blood pressure targets among SPRINT-eligible
real world adults with CKD. In Aim 2, we will develop and validate models for individualized prediction of
intensive blood pressure treatment effects, and illustrate the application in real world CKD populations. In Aim
3, we will emulate a sequential clinical trial of blood pressure medication intensification using electronic health
records in persons with CKD. Our study is important because hypertension treatment affects nearly all adults
with CKD and key evidence gaps may lead to suboptimal management in this high-risk population. It is
innovative because it will provide new evidence about the implications of intensive blood pressure targets and
new analytic approaches to support clinical decisions with real world data.
项目摘要/摘要
高血压影响着80%以上患有慢性肾脏病(CKD)的成年人,其治疗是一种
CKD管理的基石。临床指南对血压指标的建议各不相同
在慢性肾脏病中,反映了对收缩压干预试验(SPRINT)解释的不确定性
并将其外推到成人CKD患者,特别是晚期CKD患者。尽管证据来自
随机试验具有很强的内部有效性,它可能不能反映患者群体的风险收益概况
将在实践中接受治疗。我们的首要目标是评估以下各项的相对风险和收益
现实世界中患有慢性肾脏病的成年人的强化血压指标与标准血压指标。我们的次要目标是
论证新的分析方法的可行性和实用性,这些方法将因果关系从
对更广泛人群的随机试验效果。我们将通过利用电子健康来实现这些目标
来自两个涵盖1300万参保者的大型医疗保健系统的创纪录数据-退伍军人健康
南加州的行政当局和凯撒长老。为了通知我们现实世界的估计,我们将
整合来自四个不同高血压试验的个体水平的数据,这些试验涉及20,000名参与者。在目标1中,我们将
在符合短跑条件的人群中评估强化与标准血压指标的平均治疗效果
现实世界中患有慢性肾脏病的成年人。在目标2中,我们将开发和验证个性化预测模型
强化血压治疗效果,并举例说明其在现实世界CKD人群中的应用。在AIM
3、我们将利用电子健康模拟降压药物强化的序贯临床试验
慢性肾脏病患者的记录。我们的研究很重要,因为高血压治疗几乎影响到所有成年人
对于慢性肾脏病和关键证据,差距可能导致在这一高危人群中进行次优管理。它是
创新是因为它将提供关于高强度血压目标和
使用真实数据支持临床决策的新分析方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MANJULA KURELLA TAMURA其他文献
MANJULA KURELLA TAMURA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MANJULA KURELLA TAMURA', 18)}}的其他基金
A Mentoring Program in Kidney Care for Older Adults
老年人肾脏护理指导计划
- 批准号:
10449851 - 财政年份:2022
- 资助金额:
$ 64.94万 - 项目类别:
A Mentoring Program in Kidney Care for Older Adults
老年人肾脏护理指导计划
- 批准号:
10656289 - 财政年份:2022
- 资助金额:
$ 64.94万 - 项目类别:
Applying Hypertension Clinical Trials to Real World Adults with CKD
将高血压临床试验应用于现实世界中患有 CKD 的成人
- 批准号:
10364460 - 财政年份:2021
- 资助金额:
$ 64.94万 - 项目类别:
Applying Hypertension Clinical Trials to Real World Adults with CKD
将高血压临床试验应用于现实世界中患有 CKD 的成人
- 批准号:
10666583 - 财政年份:2021
- 资助金额:
$ 64.94万 - 项目类别:
Developing Tools for Dialysis Decision Support in Older Adults
开发老年人透析决策支持工具
- 批准号:
10213136 - 财政年份:2020
- 资助金额:
$ 64.94万 - 项目类别:
Developing Tools for Dialysis Decision Support in Older Adults
开发老年人透析决策支持工具
- 批准号:
10735868 - 财政年份:2020
- 资助金额:
$ 64.94万 - 项目类别:
Developing Tools for Dialysis Decision Support in Older Adults
开发老年人透析决策支持工具
- 批准号:
10450652 - 财政年份:2020
- 资助金额:
$ 64.94万 - 项目类别:
Understanding the Initiation of Maintentenance Dialysis among Older Veterans
了解老年退伍军人维持透析的开始
- 批准号:
10181033 - 财政年份:2014
- 资助金额:
$ 64.94万 - 项目类别:
Understanding the Initiation of Maintentenance Dialysis among Older Veterans
了解老年退伍军人维持透析的开始
- 批准号:
8780220 - 财政年份:2014
- 资助金额:
$ 64.94万 - 项目类别:
Understanding the Initiation of Maintentenance Dialysis among Older Veterans
了解老年退伍军人维持透析的开始
- 批准号:
10178093 - 财政年份:2014
- 资助金额:
$ 64.94万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 64.94万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 64.94万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 64.94万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 64.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists